Search results
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 3 hours agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global ...
Regeneron’s stock dips premarket after earnings fall short of estimates
Market Watch· 3 hours agoAdjusted per-share earnings came to $9.55, below the $10.20 FactSet consensus. Revenue fell 1% to...
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoSanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS,...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 2 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Zacks via Yahoo Finance· 7 days agoPharma sales increased 6.4% to €7.76 billion, mainly driven by Dupixent and new product launches. ...
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Investor's Business Daily· 7 days agoSales also fell 2.4% to $11.67 billion, but topped FactSet-polled analysts' consensus call for...
Health Care Roundup: Market Talk
The Wall Street Journal· 7 days agoThe Anglo-Swedish pharmaceutical giant’s current full-year targets are 4% below consensus, but an upgrade is likely for later this year, the analysts...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 6 days agoRilzabrutinib was added to Sanofi’s pipeline with last year’s acquisition of Principia Biopharma....
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Zacks via Yahoo Finance· 2 days agoThe Zacks Consensus Estimate for the bottom line is pegged at $10.14 per share. Investors' focus is...